热门资讯> 正文
Auria Pharmaceuticals收购Kezar Life Sciences
2026-03-30 22:06
- Aurinia Pharmaceuticals (AUPH) is acquiring Kezar Life Sciences (KZR) for $6.955 in cash per share of Kezar common stock, plus one contingent value right.
- The CVR gives the shareholder the right to receive: (i) potential payments relating to the ongoing clinical development of zetomipzomib; (ii) certain proceeds relating to Kezar’s collaboration with Everest Medicines and Kezar’s sale of its Sec61‑based discovery and development program to Enodia Therapeutics; and (iii) 100% of Kezar’s closing net cash exceeding $50M.
- Zetomipzomib is a potential first-in-class immunoproteasome inhibitor in phase 2 autoimmune hepatitis. In a phase 2 trial, zetomipzomib showed durable steroid-sparing remissions. The candidate is also under investigation for lupus nephritis and systemic lupus erythematosus.
More on Aurinia Pharma, Kezar Life Sciences
- Aurinia Pharmaceuticals: New Management, Continued Lupkynis Performance
- Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade)
- Aurinia Pharmaceuticals Inc. (AUPH) Q4 2025 Earnings Call Transcript
- Aurinia Pharmaceuticals appoints Kevin Tang as CEO
- Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
